Deflazacort
Deflazacort is a corticosteroid (steroid medicine) used to treat Duchenne muscular dystrophy (DMD), a muscle-wasting genetic condition, in children and older patients.
🧬 Where this information comes from Click to expand
The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 19 clinical label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →
Deflazacort (Emflaza) is a once-daily steroid that calms inflammation and the immune system, used for Duchenne muscular dystrophy (DMD) as one of the two standard steroid options alongside prednisone, and it is available generically. Expect real steroid effects, mostly a rounder, puffier face, belly weight gain, a bigger appetite, irritability and more colds, with infections, thinner bones, slower growth and mood changes as the longer-term concerns. The one rule never to break is stopping it suddenly, since the body comes to rely on it and the dose must come down gradually. Regular checks of blood pressure, blood sugar, bone density and eye pressure catch the slower problems early.
Clinical pearls
- Deflazacort can be taken with or without food, but never with grapefruit juice.
- Clarithromycin and fluconazole raise its levels, while rifampin, carbamazepine and phenytoin weaken it, so every new prescription needs checking.
- Get vaccines done before starting, with live vaccines at least 4 to 6 weeks ahead, and no live vaccines during treatment.
- Call the prescriber after any chickenpox or measles exposure if your child has not had them or been vaccinated.
Patient information guide A plain-language walkthrough of Deflazacort, written from its FDA label.
What Deflazacort is used for
▾
Deflazacort is used for one condition across the supported products.
- Duchenne muscular dystrophy (DMD) in patients 2 years and older: Emflaza, Jaythari, JAYTHARI oral suspension, and deflazacort oral suspension.
- DMD in patients 5 years and older: Pyquvi, Kymbee (tablet and suspension), and deflazacort tablets.
How Deflazacort works
▾
Deflazacort is a prodrug, so your body converts it to an active form called 21-desDFZ. This form works through the glucocorticoid receptor to lower inflammation and suppress the immune system.
How this helps muscles in DMD is not known.
Deflazacort dosage
▾
Deflazacort is taken by mouth once daily. The dose is based on body weight. It can be taken with or without food, but not with grapefruit juice.
- Tablets (Jaythari and Kymbee) can be swallowed whole or crushed in applesauce and taken right away.
- Suspensions (Jaythari, Pyquvi, Kymbee) should be shaken well and measured with the provided oral dispenser.
- If taken for more than a few days, the dose must be lowered gradually when stopping.
Dosing details from the FDA-approved label
From the Deflazacort prescribing information (“Dosage and Administration”). Doses are set by your prescriber for your product, condition, kidney function and age — never change a dose on your own.
- Recommended dosage (Emflaza, deflazacort oral suspension, Jaythari, Pyquvi, Kymbee)
- Approximately 0.9 mg/kg/day orally once daily
- If the oral suspension is used, round up to the nearest tenth of a milliliter (mL)
- If tablets are used, round up to the nearest possible dose
- Can be taken with or without food; do not administer with grapefruit juice; decrease dosage gradually if given for more than a few days
- Patients taking moderate or strong CYP3A4 inhibitors
- Give one third of the recommended dosage
- For example, a 36 mg per day dose would be reduced to a 12 mg per day dose
- Applies when administered with moderate or strong CYP3A4 inhibitors
Read the label’s full dosing text
2 DOSAGE AND ADMINISTRATION The recommended once-daily dosage is approximately 0.9 mg/kg/day administered orally ( 2.2 ) Discontinue gradually when administered for more than a few days ( 2.3 ) 2.1 Assessments Prior to First Dose of EMFLAZA Administer all immunizations according to immunization guidelines prior to starting EMFLAZA. Administer live-attenuated or live vaccines at least 4 to 6 weeks prior to starting EMFLAZA [see Warnings and Precautions ( 5.8 )] . 2.2 Dosing Information The recommended oral dosage of EMFLAZA is approximately 0.9 mg/kg/day once daily. If tablets are used, round up to the nearest possible dose. Any combination of the four EMFLAZA tablet strengths can be used to achieve this dose. If the oral suspension is used, round up to the nearest tenth of a milliliter (mL). 2.3 Discontinuation Dosage of EMFLAZA must be decreased gradually if the drug has been administered for more than a few days [see Warnings and Precautions ( 5.1 )] . 2.4 Important Preparation and Administration Instructions EMFLAZA Tablets and Oral Suspension can be taken with or without food. Do not administer EMFLAZA with grapefruit juice [see Drug Interactions ( 7.1 )] EMFLAZA Tablets EMFLAZA Tablets can be administered whole or crushed and taken immediately after mixing with applesauce. EMFLAZA Oral Suspension Shake EMFLAZA Oral Suspension well before administration. Use only the oral dispenser provided with the product. After withdrawing the appropriate dose into the oral dispenser, slowly add the EMFLAZA Oral Suspension into 3 to 4 ounces of juice (except grapefruit juice) or milk and mix well. The dose should then be administered immediately. Discard any unused EMFLAZA Oral Suspension remaining after 1 month of first opening the bottle. 2.5 Dosage Modification for Use with CYP3A4 Inhibitors and Inducers CYP3A4 Inhibitors Give one third of the recommended dosage when EMFLAZA is administered with moderate or strong CYP3A4 inhibitors. For example, a 36 mg per day dose would be reduced to a 12 mg per day dose when used with moderate or strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 ) and Clinical Pharmacology ( 12.3 )] . CYP3A4 Inducers Avoid use with moderate or strong CYP3A4 inducers with EMFLAZA [see Drug Interactions ( 7.1 ) and Clinical Pharmacology ( 12.3 )] .
Read the full Dosage and Administration section on DailyMed →
Deflazacort side effects
▾
The most common side effects in studies were:
Common side effects
- Cushingoid appearance (rounded, puffy face)
- Weight gain
- Increased appetite
- Excess hair growth (hirsutism)
- Central (belly) obesity
- Upper respiratory infection, cough, and stuffy or runny nose
- Frequent urination
- Irritability
- Colds, cough, and stuffy nose
When to get medical help
- Call your doctor right away if you have a skin rash. Serious skin reactions can occur, and the medicine should be stopped at the first sign of rash unless it is clearly unrelated.
- Get help for signs of infection, such as fever. Steroids can hide or worsen infections.
- Seek care for severe mood changes, depression, thoughts of suicide, hallucinations, or confusion.
- Get help for severe stomach pain, which can signal a stomach or bowel perforation.
- Seek emergency care for signs of a severe allergic reaction (anaphylaxis).
- Report vision changes or eye pain, since cataracts and glaucoma can occur.
- Call your doctor if you are exposed to chickenpox or measles and have not had them or been immunized.
Deflazacort warnings and precautions
▾
- Do not stop suddenly. Abrupt stopping can cause dangerous adrenal insufficiency, so the dose must be tapered.
- Infection risk is higher, and signs of infection may be hidden. Chickenpox and measles can be serious in non-immune people.
- Blood pressure, potassium, blood sugar, and bone density may need monitoring.
- Mood and behavior changes, cataracts, glaucoma, and slowed growth in children can occur.
- Serious skin rashes (toxic epidermal necrolysis) have been reported, usually within 8 weeks.
- Live vaccines should be avoided during treatment.
Deflazacort interactions
▾
Some medicines and foods change how much deflazacort your body has.
- CYP3A4 inhibitors (clarithromycin, fluconazole, diltiazem, verapamil, grapefruit juice): raise levels of the active form, so a lower dose may be needed.
- CYP3A4 inducers (rifampin, efavirenz, carbamazepine, phenytoin): can lower levels sharply and reduce effect.
- Neuromuscular blockers (such as pancuronium): higher risk of acute muscle weakness.
Interactions listed in the FDA-approved label
From the Deflazacort prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.
- Moderate or strong CYP3A4 inhibitors (e.g., clarithromycin, fluconazole, diltiazem, verapamil, grapefruit juice): Co-administration of deflazacort with clarithromycin, a strong CYP3A4 inhibitor, increased total exposure to the active metabolite 21-desDFZ by about 3-fold. Give one third the recommended dosage of PYQUVI.
- Moderate or strong CYP3A4 inducers (strong e.g., efavirenz; moderate e.g., carbamazepine, phenytoin): Co-administration of deflazacort with rifampin, a strong CYP3A4 inducer, significantly decreased the exposure of 21-desDFZ and may reduce efficacy. Avoid concomitant use.
- Neuromuscular blocking drugs (e.g., pancuronium): Patients receiving corticosteroids, including PYQUVI, with neuromuscular blocking drugs may be at increased risk of developing an acute myopathy.
Read the label’s full interactions text
7 DRUG INTERACTIONS Moderate or strong CYP3A4 inhibitors: Give one third of the recommended dosage of PYQUVI ( 7.1 ) Avoid use of moderate or strong CYP3A4 inducers with PYQUVI, as they may reduce efficacy ( 7.1 ) See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling. Additional pediatric use information is approved for PTC Therapeutics, Inc.'s Emflaza ® (deflazacort) oral suspension. However, due to PTC Therapeutics, Inc.'s marketing exclusivity rights, this drug product is not labeled with that information. 7.1 CYP3A4 Inhibitors and Inducers Moderate or Strong CYP3A4 Inhibitors The active metabolite of deflazacort, 21-desDFZ, is a substrate of CYP3A4 [see Clinical Pharmacology ( 12.3 )] . Co-administration of deflazacort with clarithromycin, a strong CYP3A4 inhibitor, increased total exposure to 21-desDFZ by about 3-fold. Therefore, give one third the recommended dosage of PYQUVI when moderate or strong CYP3A4 inhibitors (e.g., clarithromycin, fluconazole, diltiazem, verapamil, grapefruit juice) are used concomitantly with PYQUVI [see Dosage and Administration ( 2.5 ) and Clinical Pharmacology ( 12.3 )] . Moderate or Strong CYP3A4 Inducers Co-administration of deflazacort with rifampin, a strong CYP3A4 inducer, significantly decreased the exposure of 21-desDFZ. Avoid concomitant use of strong (e.g., efavirenz) or moderate (e.g., carbamazepine, phenytoin) CYP3A4 inducers with PYQUVI [see Dosage and Administration ( 2.5 ) and Clinical Pharmacology ( 12.3 )] . 7.2 Neuromuscular Blockers Patients receiving corticosteroids, including PYQUVI, and concomitant therapy with neuromuscular blocking drugs (e.g., pancuronium) may be at increased risk of developing an acute myopathy [see Warnings and Precautions ( 5.11 )] .
Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.
Before taking Deflazacort
▾
- Do not use if you are allergic to deflazacort or its inactive ingredients.
- Get vaccines up to date before starting.
- Tell your doctor about infections, heart failure, high blood pressure, kidney, thyroid, stomach, or eye problems, or diabetes.
- Pregnancy and breastfeeding: discuss risks and benefits with your doctor.
- Children: the oral suspension contains benzyl alcohol and is not approved under age 2.
- Older adults: DMD mainly affects children and young adults, so there is no experience in older adults.
- Kidney problems: no dose adjustment needed. Mild or moderate liver problems: no adjustment needed.
Deflazacort overdose
▾
For a sudden overdose, treatment is immediate stomach emptying (lavage or vomiting) followed by supportive care. For long-term overdose in someone who needs ongoing steroids, the dose may be lowered temporarily or alternate-day dosing may be used. Contact a doctor or poison control right away.
What Deflazacort does in the body
▾
Deflazacort’s active form acts on glucocorticoid receptors to produce anti-inflammatory and immune-suppressing effects. How it benefits people with DMD is not fully known.
How your body processes Deflazacort
▾
After a dose by mouth, blood levels peak in about 1 hour. Food does not change how much is absorbed, and tablets and suspension are absorbed similarly. Esterase enzymes quickly convert it to its active form, which CYP3A4 then breaks down. About 68% leaves in the urine, and elimination is almost complete within 24 hours.
How to store Deflazacort
▾
Store at 20ºC to 25ºC (68ºF to 77ºF); excursions permitted between 15°C to 30°C (59°F to 86°F) .
Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →
Supplements & herbs that interact with Deflazacort
180 supplements and herbal products have documented interactions with Deflazacort in the licensed clinical database we use. Most are manageable — but your pharmacist should know about everything you take, including vitamins and herbals.
- Major · 3
- Moderate · 139
- Minor · 38
Educational information from a licensed clinical database (Natural Medicines) — see our data sources & update cadence. Not medical advice: an interaction being documented does not mean it will happen to you; do not start or stop medications or supplements without professional guidance.
Deflazacort: pharmacist answers to common questions
Quick, plain-English answers to the questions patients ask most about Deflazacort — the kind of thing our pharmacy team would talk through with you at the counter.
What is deflazacort for?
▾
How do I take it?
▾
Can I stop it if my child feels fine?
▾
What side effects should I expect?
▾
Does it interact with other medicines?
▾
What about vaccines?
▾
Is Deflazacort available over the counter?
▾
When was Deflazacort first available?
▾
Who makes Deflazacort?
▾
Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →
More about Deflazacort on HelloPharmacist
Deflazacort forms and strengths (how it comes)
Deflazacort is available in 2 forms. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.
Need a version that does not list lactose, a gluten source, a dye or gelatin? Inactive ingredients differ by manufacturer: see Deflazacort inactive ingredients by manufacturer.
Tablet
How this form is used
- Emflaza and Jaythari tablets are labeled for DMD in patients 2 years and older.
- Kymbee and deflazacort tablets are labeled for DMD in patients 5 years and older.
- Jaythari and Kymbee tablets can be swallowed whole or crushed and taken right away mixed with applesauce.
- Kymbee, Jaythari, and Emflaza tablets can be taken with or without food.
- Any combination of the available tablet strengths can be used to reach the prescribed dose.
Oral suspension
How this form is used
- Emflaza and JAYTHARI oral suspension are labeled for DMD in patients 2 years and older.
- Pyquvi and Kymbee oral suspension are labeled for DMD in patients 5 years and older.
- Pyquvi, Kymbee, and JAYTHARI oral suspension should be shaken well before use.
- Pyquvi, Kymbee, and JAYTHARI oral suspension should be measured only with the oral dispenser provided.
- Emflaza oral suspension doses are rounded up to the nearest tenth of a milliliter.
- Emflaza and Pyquvi oral suspension can be taken with or without food.
Deflazacort on the U.S. market: products, makers and brands
How Deflazacort appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
11 companies list 54 Deflazacort product records with the FDA, mostly as tablet, oral suspension; the earliest marketing or approval year on record is 2008. Brand names on the directory include Emflaza, Jaythari, Pyquvi and 2 more; the rest are generics.
FDA-listed product records by dose form (tablet variants merged) — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
Also listed with the FDA, not a patient dose form: Powder (8) — bulk drug substance sold to compounders/manufacturers and multi-item kits. These aren’t counted in the dose-form total above.
Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
How widely Deflazacort is used (Medicaid data)
A general measure of how commonly Deflazacort is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.
Think of this as a proxy for how widely Deflazacort is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.
How commonly is Deflazacort prescribed? Of the 1,601 medications we measure, Deflazacort ranks #882 by Medicaid prescriptions — more than 45% of them.
Utilization by Deflazacort product
Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.
deflazacort 22.75 MG/ML Oral Suspension Most dispensed
Summed across the 2 of 9 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1870964
deflazacort 30 MG Oral Tablet
Summed across the 3 of 10 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 153880
deflazacort 18 MG Oral Tablet
Summed across the 2 of 10 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1870954
deflazacort 6 MG Oral Tablet
Summed across the 2 of 10 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 153098
deflazacort 36 MG Oral Tablet
Summed across the 2 of 10 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1870958
Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.
Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Deflazacort, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 11 of 49 listed Deflazacort NDCs with Medicaid activity.
Compare Deflazacort products
A representative set of FDA-listed product records for Deflazacort — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)
| Strength | Route | Manufacturer / Labeler | Category ⓘ | Details |
|---|---|---|---|---|
| 💊Oral suspension | ||||
| 22.75 mg/mL | Oral | Aucta Pharmaceuticals, Inc. | ANDA | View NDC → |
| 22.75 mg/mL | Oral | Biocon Pharma Inc. | ANDA | View NDC → |
| 22.75 mg/mL | Oral | Cranbury Pharmaceuticals, LLC | ANDA | View NDC → |
| 22.75 mg/mL | Oral | Doppel Farmaceutici S.r.l. × 2 listings | ANDA | View NDC → |
| 22.75 mg/mL | Oral | PTC Therapeutics, Inc. | NDA | View NDC → |
| 22.75 mg/mL | Oral | Sun Pharmaceutical Industries, Inc. | ANDA | View NDC → |
| 22.75 mg/mL | Oral | Upsher-Smith Laboratories, LLC | ANDA | View NDC → |
| 22.75 mg/mL | Oral | Zydus Pharmaceuticals (USA) Inc. × 2 listings | ANDA | View NDC → |
| 💊Tablet | ||||
| 6 mg | Oral | Amneal Pharmaceuticals NY LLC | ANDA | View NDC → |
| 18 mg | Oral | Amneal Pharmaceuticals NY LLC | ANDA | View NDC → |
| 30 mg | Oral | Amneal Pharmaceuticals NY LLC | ANDA | View NDC → |
| 36 mg | Oral | Amneal Pharmaceuticals NY LLC | ANDA | View NDC → |
| 6 mg | Oral | Aurobindo Pharma Limited | ANDA | View NDC → |
| 18 mg | Oral | Aurobindo Pharma Limited | ANDA | View NDC → |
| 30 mg | Oral | Aurobindo Pharma Limited | ANDA | View NDC → |
| 36 mg | Oral | Aurobindo Pharma Limited | ANDA | View NDC → |
| 6 mg | Oral | AvKARE | ANDA | View NDC → |
| 18 mg | Oral | AvKARE | ANDA | View NDC → |
| 30 mg | Oral | AvKARE | ANDA | View NDC → |
| 36 mg | Oral | AvKARE | ANDA | View NDC → |
| 6 mg | Oral | Doppel Farmaceutici S.r.l. × 2 listings | ANDA | View NDC → |
| 18 mg | Oral | Doppel Farmaceutici S.r.l. × 2 listings | ANDA | View NDC → |
| 30 mg | Oral | Doppel Farmaceutici S.r.l. × 2 listings | ANDA | View NDC → |
| 36 mg | Oral | Doppel Farmaceutici S.r.l. × 2 listings | ANDA | View NDC → |
| 6 mg | Oral | PTC Therapeutics, Inc. | NDA | View NDC → |
| 18 mg | Oral | PTC Therapeutics, Inc. | NDA | View NDC → |
| 30 mg | Oral | PTC Therapeutics, Inc. | NDA | View NDC → |
| 36 mg | Oral | PTC Therapeutics, Inc. | NDA | View NDC → |
| 6 mg | Oral | Sun Pharmaceutical Industries, Inc. | ANDA | View NDC → |
| 18 mg | Oral | Sun Pharmaceutical Industries, Inc. | ANDA | View NDC → |
| 30 mg | Oral | Sun Pharmaceutical Industries, Inc. | ANDA | View NDC → |
| 36 mg | Oral | Sun Pharmaceutical Industries, Inc. | ANDA | View NDC → |
| 6 mg | Oral | Upsher-Smith Laboratories, LLC × 2 listings | ANDA | View NDC → |
| 18 mg | Oral | Upsher-Smith Laboratories, LLC × 2 listings | ANDA | View NDC → |
| 30 mg | Oral | Upsher-Smith Laboratories, LLC × 2 listings | ANDA | View NDC → |
| 36 mg | Oral | Upsher-Smith Laboratories, LLC × 2 listings | ANDA | View NDC → |
| 6 mg | Oral | Zydus Pharmaceuticals (USA) Inc. × 2 listings | ANDA | View NDC → |
| 18 mg | Oral | Zydus Pharmaceuticals (USA) Inc. × 2 listings | ANDA | View NDC → |
| 30 mg | Oral | Zydus Pharmaceuticals (USA) Inc. × 2 listings | ANDA | View NDC → |
| 36 mg | Oral | Zydus Pharmaceuticals (USA) Inc. × 2 listings | ANDA | View NDC → |
Showing 54 of 54 products — FDA National Drug Code Directory. See every product, package size and price: browse all 54 Deflazacort NDCs →
Deflazacort side effects reported to the FDA (FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Deflazacort — a signal of what to watch for, not proof the drug caused it.
The effects most often named in FDA reports that mention Deflazacort are weight increased, fall, vomiting; about 51% of the reports were classed as serious. These are voluntary reports, so they show what people report, not how often it happens.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Deflazacort in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
Deflazacort FDA approval history
How Deflazacort went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Deflazacort was first approved by the FDA in 2008; the first generic version was approved in 2024. It remains available in U.S. pharmacies today.
Source: Drugs@FDA.
Deflazacort recall history
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
The FDA’s enforcement reports list no Deflazacort recalls since July 2021.
✅No Deflazacort recalls on record since July 2021Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Sep 24, 2026.
RxNorm Concept Web — From Ingredient to Every Form and Strength
This page starts with one ingredient concept (IN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). Combination products remain separate concepts with their own pages.
RxCUI 22396 2 dose forms · 6 strengths
-
Dose form (SCDF) Oral Suspension RxCUI 1870963In current FDA listingsClinical drug / strength (SCD) 22.75 MG/MLRxCUI 1870964 -
Dose form (SCDF) Oral Tablet RxCUI 371693In current FDA listings
Look up RxCUI 22396 in the RxCUI Atlas →
RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.
Deflazacort supply and shortage status
Whether Deflazacort is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Source: openFDA, from the FDA Drug Shortages database.
Deflazacort brand names
Deflazacort is sold under 5 brand names in the FDA directory — Emflaza, Jaythari, Pyquvi, Kymbee and others. A brand and its generic contain the same active ingredient; the brand name belongs to one company's product.
Who makes Deflazacort: manufacturers and labelers
11 companies list Deflazacort products with the FDA. By number of product records, the largest are Doppel Farmaceutici S.r.l., Zydus Pharmaceuticals (USA) Inc., Upsher-Smith Laboratories, LLC. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.
Deflazacort drug class (RxNorm)
Deflazacort belongs to the Corticosteroid class.
Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.
Sources for this Deflazacort page
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How this page is built
HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. PTC Therapeutics, Inc. is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →